Zai Lab Announces Second Quarter 2023 Financial Results and Corporate Updates
- Total product revenue of
$68.9 millionfor the second quarter of 2023, representing 45% y-o-y growth; 53% y-o-y growth at constant exchange rate
- VYVGART® (efgartigimod alfa injection) approved in
Chinaas first-and-only neonatal Fc receptor (FcRn) blocker for generalized myasthenia gravis (gMG); preparations for launch underway; subcutaneous efgartigimod for gMG under Biologics License Application (BLA) review
- Primary endpoint met in ADHERE trial of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for treatment of chronic inflammatory demyelinating polyneuropathy (CIDP)
- Strong balance sheet with a cash position of
$876.4 millionas of June 30, 2023, compared to $931.4 millionas of March 31, 2023
- Company to host conference call and webcast on
August 8, 2023, at 8:00 a.m. ET
“In the second quarter of 2023, we continued to successfully execute across our business. Our commercial products continued to deliver strong growth, with net product revenues growing 53% on a constant currency basis, and we made important progress for several late-stage and early development programs within our pipeline,” said Dr.
Recent Product Highlights and Corporate Updates
We continued to increase sales for each of our commercial products in the second quarter of 2023, compared to the same period in 2022, driven by increased access for ZEJULA®, QINLOCK®, and NUZYRA® as a result of their inclusion in the National Reimbursement Drug List (NRDL) and for Optune® as a result of increased supplemental insurance plan coverage.
We also received the following regulatory approvals for our commercial products during the second quarter of 2023:
- VYVGART®: In
June 2023, we received approval from the NMPA for the BLA for VYVGART (efgartigimod alfa injection), a first-in-class FcRn antagonist, as an add on standard therapy for the treatment of adult patients with gMG who are anti-acetylcholine receptor (AChR) antibody positive. We expect to commercially launch VYVGART in mainland Chinalater this year.
- Optune: In
May 2023, the Taiwan Food and Drug Administrationapproved the Marketing Authorization Application (MAA) of Optune for the treatment of patients with glioblastoma multiforme (GBM).
Key Product Candidate Developments
We continued to advance our product candidates through our research and development and commercial operations, including the following developments with respect to our clinical trials and regulatory approvals:
- ZEJULA (niraparib, PARP): In
July 2023, data from the Phase 3 PRIME study were published in JAMA Oncology, supporting the utility of ZEJULA as a maintenance therapy in a broad population of Chinese patients with newly diagnosed advanced ovarian cancer and demonstrating that an individual starting dose (ISD) of 200 or 300mg based on baseline bodyweight and platelet count can bring significant benefit to patients with an improved safety and tolerability profile of ZEJULA compared to a fixed 300mg starting dose. These data demonstrate that maintenance treatment with ZEJULA can significantly prolong progression-free survival versus placebo and can reduce the risk of disease progression or death by 55% with newly diagnosed advanced ovarian cancer.
- Tumor Treating Fields (TTFields or Optune):
- Pancreatic Cancer: In
July 2023, Zai Labpartner NovoCure Limited (NovoCure) announced a favorable Independent Data Monitoring Committee recommendation to continue the Phase 3 PANOVA-3 clinical trial of TTFields therapy in pancreatic cancer. Pre-specified interim analysis concluded that the fully enrolled PANOVA-3 clinical trial should proceed to final analysis as planned. Zai Labparticipated in the Greater Chinaportion of the study.
- NSCLC: In
June 2023, Zai Laband NovoCure announced the LUNAR Phase 3 clinical trial met the primary endpoint, demonstrating a statistically significant and clinically meaningful extension in overall survival for patients with metastatic NSCLC after platinum-based therapies. Zai Labparticipated in the Greater Chinaportion of the study.
- Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities; and
- Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival.
- Pancreatic Cancer: In
- KRAZATI® (adagrasib, KRASG12C):
July 2023, Zai Labcompleted enrollment in Chinafor the global Phase 3 KRYSTAL-10 trial of adagrasib in combination with cetuximab vs. chemotherapy in patients with previously treated advanced KRASG12C-mutated colorectal cancer.
June 2023, Zai Labcompleted enrollment in Chinafor the global Phase 2 KRYSTAL-7 trial of adagrasib in combination with pembrolizumab as first-line treatment for patients with advanced KRASG12C-mutated NSCLC.
- Repotrectinib (ROS1/TRK): In
June 2023, Zai Labannounced that the National Medical Products Administration(NMPA) in Chinahas accepted its New Drug Application (NDA) for repotrectinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC, after granting priority review in May 2023. In May 2023, Zai Labpartner Bristol Myers Squibb(BMS) announced that the NDA for repotrectinib was accepted for priority review by the FDA for the same indication, with a Prescription Drug User Fee Act (PDUFA) date of November 27, 2023.
- Bemarituzumab (FGFR2b): In
July 2023, Zai Labenrolled the first patient in the mainland Chinaportion of the global Phase 3 FORTITUDE-101 study of bemarituzumab plus chemotherapy, versus placebo plus chemotherapy, in first-line gastric cancer with FGFR2b overexpression.
Autoimmune Disorders, Infectious Diseases and Neuroscience
- VYVGART (efgartigimod, FcRn):
- gMG: In
June 2023, argenx BV (argenx) announced that the FDA approved VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) injection for subcutaneous use in gMG. In July 2023, the NMPA accepted Zai Lab’s BLA for efgartigimod alfa injection (subcutaneous injection) for the treatment of adult patients with gMG.
- CIDP: In
July 2023, Zai Laband argenx announced positive topline results from the global registrational ADHERE study evaluating VYVGART Hytrulo in adults with CIDP. Zai Labparticipated in the Greater Chinaportion of the study. Highlights of the results include:
- Primary endpoint met (p=0.000039); VYVGART Hytrulo demonstrated a 61% reduction (HR: 0.39 95% CI: 0.25; 0.61) in the risk of relapse versus placebo;
- 67% of patients in open-label Stage A demonstrated evidence of clinical improvement (ECI), indicating that IgG autoantibodies play a significant role in the underlying biology of CIDP; and
- Safety and tolerability profile was consistent with previous clinical trials and the confirmed safety profile of VYVGART.
- Bullous pemphigoid (BP): In
May 2023, Zai Labenrolled the first patient in Chinain the global Phase 2/3 BALLAD study of SC efgartigimod in adult patients with BP.
- gMG: In
- XACDURO® (SUL-DUR,
Asia Pacificrights): In May 2023, Zai Labpartner Entasis Therapeutics, Inc.(Entasis), a wholly owned subsidiary of Innoviva, Inc., announced that the FDA approved XACDURO for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter). The Company’s NDA is under review at the NMPA with priority review status in China.
- KarXT (xanomeline-trospium, M1/M4-preferring muscarinic agonist): In
June 2023, Zai Labenrolled the first patient in the registrational bridging study in mainland Chinafor KarXT for the treatment of patients with schizophrenia.
- Organizational update: In
July 2023, Zai Labpromoted Yajing Chento Chief Financial Officer (CFO), effective July 7, 2023. Dr. Chenpreviously served as Zai Lab’s Senior Vice President and Deputy CFO, helping to oversee finance, planning and forecasting, accounting, tax, treasury, and procurement matters since joining the Company in September 2021. She is a seasoned finance executive with more than 20 years of experience in the life sciences industry as well as a Ph.D. trained scientist. She joined the Company from AstraZeneca where she held various roles of increasing responsibility from 2006 to 2021, including Chief Financial Officer for the U.S. Oncology Business Unit from 2019 to 2021 and Finance Controller of the Global Oncology Business Unit from 2016 to 2019. Her scientific background combined with her significant executive management experience, finance expertise at leading global companies, and business acumen provide a unique and valuable perspective to the Company and will help drive our next phase of growth. Dr. Chensucceeds Billy Cho, who stepped down from his role and left the Company on July 7, 2023.
- 2023 Investor Day:
Zai Labhosted an Investor Day in New Yorkon Tuesday, June 20, 2023.
Zai Labhighlighted its 5-year growth strategy, including the following goals by the end of 2028:
- Over 15 commercial-stage products in 2028 (versus 5 today)
- Over 8 clinical-stage global-right products in 2028 with at least one Investigational New Drug application (IND) per year (versus 3 today)
- Revenue compound annual growth rate (CAGR) of >50% from 2023 to 2028
- Significant revenue growth and expanding operating margins to lead to corporate profitability by the end of 2025
- Over 15 commercial-stage products in 2028 (versus 5 today)
- In addition,
Zai Labspotlighted multiple key programs with over $1 billionpeak sales potential, starting with efgartigimod.
Anticipated Major Milestones in 2023
Tumor Treating Fields or TTFields
Zai Labpartner NovoCure to provide a topline data readout from the global pivotal INNOVATE-3 clinical study testing the efficacy of TTFields together with paclitaxel in platinum-resistant ovarian cancer.
KRAZATI (adagrasib, KRASG12C)
Zai Labpartner Mirati Therapeutics, Inc. (Mirati) to provide a clinical data update for the global Phase 2 KRYSTAL-7 study of adagrasib in combination with pembrolizumab in first-line KRASG12C-mutated NSCLC. Zai Labis participating in the study in Greater China.
- Mirati to provide an update on its multi-pronged development approach in first-line KRASG12C-mutated NSCLC.
- Mirati to submit a supplemental New Drug Application (sNDA) for Accelerated Approval to the FDA in third-line+ KRASG12C-mutated advanced colorectal cancer (CRC).
Zai Labpartner Regeneron Pharmaceuticals, Inc. (Regeneron) to initiate confirmatory studies in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) including in earlier lines.
- Regeneron expects to receive BLA and Marketing Authorisation Application (MAA) acceptance in relapsed/refractory FL and DLBCL.
MARGENZA™ (margetuximab, HER2)
- Potential NMPA approval of the NDA for margetuximab in third-line+ metastatic HER2+ breast cancer.
Autoimmune Disorders, Infectious Disease and Neuroscience
VYVGART (efgartigimod, FcRn)
Zai Labpartner argenx to report topline data from the registrational Phase 3 ADDRESS trial of SC efgartigimod in pemphigus and the registrational Phase 3 ADVANCE-SC trial of SC efgartigimod in immune thrombocytopenia (ITP) in the fourth quarter of 2023. Zai Labparticipated in both studies in Greater China.
- argenx to initiate a registrational study of efgartigimod in thyroid eye disease (TED) in the fourth quarter of 2023.
KarXT (xanomeline-trospium, M1/M4-preferring muscarinic agonist)
Zai Labpartner Karuna to submit an NDA to the FDA for KarXT for the treatment of patients with schizophrenia in the third quarter of 2023.
- Karuna to initiate the Phase 3 ADEPT-2 and ADEPT-3 trials in Alzheimer’s disease psychosis.
Zai Labplans to participate in these studies in Greater China.
Second Quarter 2023 Financial Results
- Product revenues were
$68.9 millionfor the second quarter of 2023, compared to $47.6 millionfor the same period in 2022, representing 45% y-o-y growth; y-o-y growth was 53% at constant exchange rate. The increase in product revenues was primarily due to increased sales volumes and decreased negative effects from the COVID-19 pandemic. The product revenues in the second quarter of 2023, compared to the same period in 2022, included:
$43.0 millionfor ZEJULA, which increased 26% from $34.1 million; and $13.7 millionfor Optune, which increased 18% from $11.6 million; and $7.5 millionfor QINLOCK, which increased from $0.6 million; and $4.6 millionfor NUZYRA, which increased from $1.3 million.
- Research and Development (R&D) expenses were
$76.7 millionfor the second quarter of 2023, compared to $66.1 millionfor the same period in 2022. The increase in R&D expenses was primarily due to increased research activities and clinical pipeline advancement.
- Selling, General and Administrative expenses were
$67.9 millionfor the second quarter of 2023, compared to $63.4 millionfor the same period in 2022. The increase was primarily due to higher general selling expenses to support new product launches.
- Net loss was
$120.9 millionfor the second quarter of 2023, or a loss per ordinary share attributable to common stockholders of $0.13, compared to a net loss of $137.9 millionfor the same period in 2022, or a loss per ordinary share of $0.14. The decrease in net loss was primarily due to product revenue growing faster than net operating expenses.
- Cash and cash equivalents, short-term investments and restricted cash totaled
$876.4 millionas of June 30, 2023, compared to $931.4 millionas of March 31, 2023.
Conference Call and Webcast Information
Details are as follows:
Registration Link: https://register.vevent.com/register/BIb7d99f107c3347f29e117b2b7bc47034
All participants must use the link provided above to complete the online registration process in advance of the conference call. Dial-in details will be in the confirmation email which the participant will receive upon registering.
A replay will be available shortly after the call and can be accessed by visiting the Company's website.
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the
In addition to results presented in accordance with GAAP, we disclose growth rates that have been adjusted to exclude the impact of changes due to the translation of foreign currencies into
Zai Lab Forward-Looking Statements
This press release contains forward-looking statements relating to our strategy and plans; potential of and expectations for our business and pipeline programs; our goals and expectations under our 5-year growth strategy (including our expectations regarding our commercial-stage products, clinical-stage global-right products, revenue growth / CAGR, operating margins, and cash flow); the peak sales potential of our programs; capital allocation and investment strategy; clinical development programs and related clinical trials; clinical trial data, data readouts, and presentations; risks and uncertainties associated with drug development and commercialization; regulatory discussions, submissions, filings, and approvals and the timing thereof; the potential benefits, safety, and efficacy of our products and product candidates and those of our collaboration partners; the anticipated benefits and potential of investments, collaborations, and business development activities; our future financial and operating results; and financial guidance. All statements, other than statements of historical fact, included in this press release are forward-looking statements, and can be identified by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,” “potential,” “will,” “would,” and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. We may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in our forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products; (2) our ability to obtain funding for our operations and business initiatives; (3) the results of our clinical and pre-clinical development of our product candidates; (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates; (5) the effects of the COVID-19 pandemic on our business and results of operations; (6) risks related to doing business in
For more information, please contact:
Unaudited Condensed Consolidated Balance Sheets
(In thousands of
|Cash and cash equivalents||859,155||1,008,470|
|Accounts receivable (net of allowance for credit loss of
|Prepayments and other current assets||38,433||35,674|
|Total current assets||1,017,505||1,124,336|
|Restricted cash, non-current||1,791||803|
|Long term investments||5,128||6,431|
|Prepayments for equipment||665||1,396|
|Property and equipment, net||56,410||57,863|
|Operating lease right-of-use assets||18,537||19,512|
|Land use rights, net||3,067||6,892|
|Intangible assets, net||1,690||1,511|
|Liabilities and shareholders’ equity|
|Current operating lease liabilities||7,299||7,050|
|Other current liabilities||59,024||66,818|
|Total current liabilities||133,354||139,842|
|Non-current operating lease liabilities||11,755||13,343|
|Other non-current liabilities||325||—|
|Commitments and contingencies|
|Ordinary shares (par value of
|Additional paid-in capital||2,932,053||2,893,120|
|Accumulated other comprehensive income||52,180||25,685|
|Treasury Stock (at cost, 4,789,110 and 2,236,280 shares as of
|Total shareholders’ equity||932,314||1,045,595|
|Total liabilities and shareholders’ equity||1,106,373||1,220,140|
Unaudited Condensed Consolidated Statements of Operations
(In thousands of
|Three Months Ended
||Six Months Ended
|Product revenue, net||68,864||47,575||131,661||93,670|
|Cost of sales||(23,763||)||(17,407||)||(45,100||)||(33,051||)|
|Research and development||(76,682||)||(66,084||)||(125,153||)||(119,938||)|
|Selling, general, and administrative||(67,920||)||(63,401||)||(130,430||)||(120,392||)|
|Gain on sale of intellectual property||10,000||—||10,000||—|
|Loss from operations||(89,501||)||(98,716||)||(159,022||)||(178,481||)|
|Foreign currency loss||(40,079||)||(34,895||)||(31,167||)||(32,610||)|
|Other expense, net||(1,405||)||(5,497||)||(171||)||(10,378||)|
|Loss before income tax and share of loss from equity method investment||(120,895||)||(137,933||)||(170,039||)||(220,106||)|
|Income tax expense||—||—||—||—|
|Share of loss from equity method investment||—||—||—||(221||)|
|Net loss attributable to ordinary shareholders||(120,895||)||(137,933||)||(170,039||)||(220,327||)|
|Loss per share - basic and diluted||(0.13||)||(0.14||)||(0.18||)||(0.23||)|
|Weighted-average shares used in calculating net loss per ordinary share - basic and diluted||964,817,310||957,684,820||963,140,360||956,603,250|
|Loss per American Depositary Shares (“ADS”) - basic and diluted||(1.25||)||(1.44||)||(1.77||)||(2.30||)|
|Weighted-average ADSs used in calculating net loss per ADS - basic and diluted||96,481,731||95,768,482||96,314,036||95,660,325|
Zai Lab Limite
Unaudited condensed consolidated statements of comprehensive loss
(In thousands of
|Three Months Ended
||Six Months Ended
|Other comprehensive income, net of tax of nil:|
|Foreign currency translation adjustments||34,908||30,325||26,495||28,132|
(In thousands of
|Three Months Ended
||Year over Year % Growth||Six Months Ended
||Year over Year % Growth|
|2023||2022||As reported||At CER*||2023||2022||As reported||At CER*|
|Product revenue, net||68,864||47,575||45||%||53||%||131,661||93,670||41||%||50||%|
|Loss from operations||(89,501||)||(98,716||)||(9||)%||(5||)%||(159,022||)||(178,481||)||(11||)%||(6||)%|
* The growth rates at constant exchange rates (“CER”) were calculated assuming the same foreign currency exchange rates were in effect for the current and prior year periods.
Source: Zai Lab Limited